Table 3.

Reasons for discontinuation of first and second-line biologics

	First Biologic					Second Biologic
	Number of discontinuations (n)	Annual rate of discontinuation (95% CI)	Survival time (years)			Number of discontinuations (n)	Annual rate of discontinuation (95% CI)	Survival time (years)
			25%	50%	75%			25%	50%	75%
Side effect	309	0.63 (0.56 to 0.71)	0.33	1	2	100	0.81 (0.67 to 0.99)	0.25	0.67	1.67
Inefficacy	209	0.47 (0.41 to 0.54)	0.5	1.17	3	93	0.57 (0.47 to 0.70)	0.42	0.92	2.42
Costs	83	0.42 (0.34 to 0.52)	0.58	1.67	4.08	51	0.51 (0.39 to 0.67)	0.58	1.42	2.92
Other	172	0.39 (0.34 to 0.45)	0.67	1.92	3.75	72	0.48 (0.38 to 0.61)	0.5	1.25	2.42
Not specified	327	0.46 (0.41 to 0.51)	0.5	1.08	3.33	221	0.51 (0.44 to 0.58)	0.5	1	2.5